All In Biotech

Drug Trial Radar · NCT03722420

Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)

A Phase III, Multi-center, Open-Label, Randomized Study of the Efficacy of Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Chinese Patients in Chronic Phase

Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 238 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

238

Planned (sponsor's estimate)

Start

Dec 28, 2018

Primary completion

Mar 3, 2023

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Il-Yang Pharm. Co., Ltd.Industry
Sponsor type
Industry
First posted
Oct 29, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III, multi-center, open-label, parallel, 2-arm, randomized study to evaluate the efficacy and safety of radotinib 300 mg Bis In Die(BID) versus imatinib 400 mg Quaque Die(QD). This study will be conducted in Chinese patients with newly diagnosed Ph+ Chronic Myelogenous Leukemia(CML)-Chronic Phase(CP) who are previously untreated for Chronic Myelogenous Leukemia(CML).

Conditions

  • Chronic Myeloid Leukemia, Chronic Phase

Interventions

  • RadotinibDrug

    Patients randomized to the radotinib arms will receive 300 mg of radotinib BID (1 in the morning and 1 in the evening, at approximately 12-hour intervals).

  • ImatinibDrug

    Patients randomized to the imatinib 400 mg arm will receive imatinib once a day throughout the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The MMR rateTime frame: at 12 months after radotinib or imatinib treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital(北京大学人民医院)

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.